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Research
Mouse allergen exposure is a well­recognized   
risk factor for allergic sensitization and 
asthma in occupational settings (Bush and 
Stave 2003; Phipatanakul 2002). More 
recently, it has also been identified as a fac­
tor that may contribute to asthma morbidity 
in nonoccupational populations. Exposure 
and sensitization to mouse allergen are com­
mon, particularly among asthmatic popu­
lations in inner cities (Phipatanakul et al. 
2000a, 2000b). In the National Cooperative 
Inner­City Asthma Study (NCICAS), which 
was the first study to examine mouse allergen 
exposures in residential environments, mouse 
allergen was detectable in an extraordinarily 
high percentage of the homes (74–100%) 
(Phipatanakul et al. 2000a). Findings from 
previous studies suggest that sensitization rates 
to mouse allergen increase with increasing 
exposure levels, although the dose–response 
relationship may not be linear (Matsui et al. 
2007). Reported sensitization rates have 
generally ranged from 7% to 18% (Matsui 
et al. 2005; Phipatanakul et al. 2000b, 2007), 
although even higher rates have been reported 
(up to 40%) among asthmatic children with 
high exposure levels (Matsui et al. 2007). 
Recent studies have also demonstrated that 
elevated mouse allergen levels are associated 
with asthma morbidity in inner­city children 
and adults, high  lighting the importance of 
mouse allergen in this population (Chew et al. 
2006; Matsui et al. 2006).
Although most studies that have been 
published have targeted inner­city populations 
(Chew et al. 2003, 2006; Matsui et al. 2005, 
2006, 2007; Phipatanakul et al. 2000a, 2000b), 
mouse allergen exposure may not be restricted 
to urban populations that have disproportion­
ately high asthma prevalence rates. Studies have 
shown that mouse allergen exposure and mouse 
sensitivity can be surprisingly widespread, even 
outside inner­city areas (Matsui et al. 2004; 
Phipatanakul et al. 2005). Yet the role of resi­
dential mouse allergen exposure in asthma 
remains poorly characterized among the general 
U.S. population because previous studies have 
focused mainly on selected populations (i.e., 
children, asthmatics, and urban residents).
The National Survey of Lead and Allergens 
in Housing (NSLAH) was the first popula­
tion­based study to estimate mouse allergen 
levels and examine mouse allergen exposure 
in relation to asthma in a nationally representa­
tive sample of the U.S. households (Vojta et al. 
2002). We have previously described the details 
of the exposure characteristics (Cohn et al. 
2004). In this article, we report associations 
between mouse allergen exposures and asthma­
related symptoms in the study population.
Materials and Methods
Study design and procedures. The NSLAH 
was a cross­sectional study that used a com­
plex, multistage design to sample the U.S. 
population of permanently occupied, 
noninstitutional housing units that permit 
resident children. The survey was approved 
by the National Institute of Environmental 
Health Sciences Institutional Review Board in 
1998, and all study procedures complied with 
applicable regulations. A detailed description 
of the study design and methodology can be 
found elsewhere (Vojta et al. 2002). Briefly, 
the survey examined a nationally represen­
tative sample of 831 housing units, inhab­
ited by 2,456 individuals, within 75 different 
locations throughout the United States. After 
an adult representative of the household gave 
written informed consent, information on 
demographics, household characteristics, 
and occupants’ health status was collected by 
questionnaire. During the home visit, envi­
ronmental data were also acquired by sample 
collection and inspection of the housing unit.
Assessment of asthma-related outcomes. 
The resident questionnaire obtained informa­
tion on doctor­diagnosed asthma and allergies, 
wheezing, asthma symptoms in the preceding 
year, and current asthma medication use. In 
this survey, an adult respondent identified 
individual household members who had doc­
tor­diagnosed asthma, including adults with 
childhood­onset asthma. Current asthma, 
which was our primary outcome meas  ure, 
was ascertained with a question confirming 
asthma symptoms in the past year. Atopic 
status was assessed by report of physician diag­
nosis of allergies (e.g., hay fever, skin, or food 
allergies); subjects with reported physician­
diagnosed allergies were classified as atopic, 
whereas subjects without reported allergies 
were considered nonatopic in the analyses.
Environmental sampling. Single sur­
face dust samples were collected from a bed, 
from a sofa or a chair, and from bedroom, 
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living room, and kitchen floors, as previously 
described (Vojta et al. 2002). Each sampling 
site was vacuumed for 5 min using a Eureka 
Mighty­Mite 7.0­A vacuum cleaner (Eureka 
Company, Bloomington, IL). We measured 
concentrations of mouse allergen [mouse uri­
nary protein (MUP)] in dust with a competi­
tive inhibition enzyme­linked immunosorbent 
assay using purified antigen and a polyclonal 
anti­MUP antibody (Greer Laboratories, Inc., 
Lenoir, NC). The lower limit of detection 
(LOD) was 0.004 µg/mL. Because of differ­
ences in extraction concentrations, the LOD 
for MUP per gram of dust varied slightly, 
being 0.25 µg/g for most of the samples 
(Cohn et al. 2004; Vojta et al. 2002).
Statistical analyses. For the statistical 
analy  ses, we log­transformed MUP concen­
trations because of skewed distributions. In 
addition to the site­specific concentrations 
(n = 5), we calculated a house index (i.e., the 
mean of all measured sampling location con­
centrations) to represent the average MUP 
concentration in the household. In 17.7% of 
the households, MUP levels were lower than 
the LOD. To maximize the number of sam­
ples in the analysis, we assigned samples with 
concentrations less than the LOD to one­half 
of the value of the LOD. Samples that had 
insufficient amount of dust for the allergen 
analysis were considered missing. Allergen 
measurements were available from at least 
one room for 99.2% (n = 824) of the homes. 
For the site­specific analyses, the correspond­
ing percentage varied from 78.9% to 88.5%, 
being lowest for living room upholstery and 
highest for kitchen floors.
We calculated odds ratios (ORs) with 
95% confidence intervals (CIs) for the asthma­
related outcomes using logistic regression. 
We excluded from the analyses subjects with 
missing data on the exposures and covariates, 
leaving 2,028 of 2,456 subjects in the analy­
sis (83%). The characteristics of the excluded 
subjects did not differ from those included 
in the analyses [see Supplemental Material, 
Table 1 (http://www.ehponline.org/mem­
bers/2008/11847/suppl.pdf)]. The models 
we present here are adjusted for age, sex, race, 
education, smoking, and survey season. We 
used household­level data (indoor smoking in 
the home) to assess smoking exposure because 
the survey did not obtain information on per­
sonal smoking. Adjusting for other social and 
household factors (e.g., income, housing type) 
did not change the ORs appreciably [< 10%; 
see Supplemental Material, Table 2 (http://
www.ehponline.org/members/2008/11847/
suppl.pdf)]. We also examined whether the 
effect estimates were influenced by dust 
weight and presence of other indoor allergens 
[Dermatophagoides farinae 1 (Der f 1, dust mite 
allergen), Dermatophagoides pteronyssinus 1 
(Der p 1, dust mite allergen), Blattella german-
ica 1 (Bla g 1, cockroach allergen), Felis domes-
ticus 1 (Fel d 1, cat allergen), Canis familiaris 1 
(Can f 1, dog allergen), and Alternaria alternata 
(mold)] and bacterial lipopolysaccharide (endo­
toxin). Because the observed association was 
modified by atopic status, we present separate 
ORs for atopic and nonatopic individuals.
We conducted logistic modeling using 
SUDAAN (version 9.0; RTI International, 
Research Triangle Park, NC), and we used 
Taylor series linearization methods to adjust 
standard errors for the complex survey design. 
We applied sample weights to all estimates 
to account for housing selection probabili­
ties, nonresponse, and poststratification. The 
SUDAAN software also took into account 
effects of clustering in the data, including 
multiple occupants in the same household. 
Details of statistical weighting for the NSLAH 
can be found elsewhere (Vojta et al. 2002). 
We further characterized the relationship 
between current asthma and MUP concentra­
tions by generalized additive models (GAMs). 
We used the gam( ) function of the GAM 
package in R software (version 2.4.0, open 
source: http://cran.r­project.org/) to fit the 
models and graphed the fitted model relation­
ships (R Foundation 2008).
Results
Table 1 presents the weighted characteristics 
of the study population. The characteristics 
of the survey sample, including distributions 
of housing characteristics, socioeconomic, 
and demographic factors, were very similar to 
charac  teristics obtained from other national 
surveys (Vojta et al. 2002). The prevalence of 
asthma was comparable with other national 
estimates (Centers for Disease Control and 
Prevention 2006). The lifetime prevalence of 
doctor­  diagnosed asthma was 11.2%, and 6.9% 
of the study subjects reported active asthma 
symptoms in the past 12 months. Most of the 
current asthmatics (77%) reported doctor­ 
diagnosed allergies and used asthma medication 
(71%). Recent wheezing was more commonly 
reported than were asthma symptoms and did 
not differ from other national estimates (Arif 
et al. 2003; Eldeirawi and Persky 2004).
Exposure distributions are summarized in 
Figure 1 of the Supplemental Material (http://
www.ehponline.org/members/2008/11847/
suppl.pdf). Most of the homes (82%) had 
detectable levels of MUP. In 35% of the 
homes, MUP concentration in at least one 
site in the household exceeded 1.6 µg/g, a level 
that has been associated with increased mouse 
allergen sensitization rates (Phipatanakul et al. 
2000b). Of the sampled sites, kitchens had 
highest concentrations (geometric mean = 
0.52 µg/g) and living room upholstery had 
lowest concentrations (geometric mean = 
0.28 µg/g) of MUP. Elevated MUP levels were 
most prevalent in multifamily homes (e.g., 
high­rise apartments) and mobile homes, older 
homes, and low­income homes. More detailed 
information on exposure characteristics has 
been published elsewhere (Cohn et al. 2004).
Table 1. Characteristics of the NSLAH population.
Characteristic  No. (%)a 
Age (years)
  < 18  762 (26.8)
  ≥ 18  1,643 (73.2)
Sex
  Male  1,189 (48.2)
  Female  1,256 (51.8)
Race
  White  1,788 (79.9)
  Black  355 (11.6)
  Other  262 (8.5)
Educationb
  High school level or lower  758 (29.7)
  Above high school level  1,646 (70.3)
Living with smoker(s)
  Yes  1,124 (46.0)
  No  1,320 (54.0)
Doctor-diagnosed asthmac
  Yes  278 (11.2)
  No  2,162 (88.8)
Current asthma 
  Yes  174 (6.9)
  No  2,265 (93.1)
Wheezing in the preceding year
  Yes  353 (15.8)
  No  1,966 (84.2)
Wheezing in the preceding month
  Yes  285 (13.0)
  No  2,098 (87.0)
Doctor-diagnosed allergiesc
  Yes  568 (28.1)
  No  1,558 (71.9)
Doctor-diagnosed hay feverc
  Yes  309 (16.2)
  No  1,767 (83.8)
aWeighted for the multistage sampling design of the 
NSLAH. bHighest education level attained in the house-
hold. cLifetime diagnosis.
Table 2. Prevalence of asthma and allergy-related outcomes and MUPa levels in the home.
  MUP ≤ 1.6 µg/g  MUP > 1.6 µg/g 
Outcome  No.  % (SE)  No.   % (SE)  p-Valueb
Doctor-diagnosed asthma  164  10.2 (1.0)  114  13.5 (2.0)  0.11
Current asthma   96  6.0 (0.8)   78  8.9 (1.4)  0.05
Wheezing in the preceding year  228  15.7 (1.5)  125  16.6 (2.0)  0.73
Wheezing in the preceding month  171  12.0 (1.6)  114  15.4 (2.3)  0.29
Doctor-diagnosed allergies  368  28.6 (1.8)  197  27.4 (3.0)  0.73
Doctor-diagnosed hay fever  200  16.2 (1.4)  109  16.6 (2.6)  0.88
aMUP concentrations were dichotomized into high and low levels; concentration was considered high if allergen concen-
tration exceeded the cut point value in any of the sampling locations. bChi square statistics.Residential exposure to mouse allergen and asthma
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Prevalence of current asthma was signifi­
cantly higher if MUP levels exceeded 1.6 µg/g 
in any location in the home (Table 2). Table 3 
shows unadjusted and adjusted effect estimates 
for the association between current asthma 
and elevated MUP levels. Table 4 presents 
ORs for atopic and nonatopic individuals 
separately because atopic status modified the 
observed association. In atopic individuals, 
elevated levels of MUP significantly increased 
the odds of having asthma symptoms in the 
past year (adjusted OR = 1.93; 95% CI, 
1.14–3.27). We found no association in non­
atopic individuals (adjusted OR = 0.69; 95% 
CI, 0.33–1.44). After adjusting for poten­
tial confounders, including other indoor 
allergens, endotoxin, or dust weight, the 
magnitude of the effect did not change appre­
ciably (Table 4). Consistent with these results, 
asthma medication use—which often suggests 
persistent and/or more severe asthma—was 
also positively associated with elevated MUP 
levels among atopic individuals (adjusted OR 
= 1.86; 95% CI, 1.03–3.36).
To further characterize the relationship 
between current asthma and MUP levels in 
the home, we modeled the allergen concentra­
tion as a continuous variable. Figure 1 pres­
ents results from logistic regression analysis. 
The adjusted ORs for current asthma corre­
spond to a 2­fold increase in MUP concentra­
tions (site­specific and average concentration 
in the household). Complementary to logistic 
regression, we modeled the association using 
GAMs. The modeled relationships display 
trends in current asthma prevalence across 
MUP concentrations. The smooth plots 
(Figure 2) illustrate adjusted prevalence for 
the average and site­specific concentrations. 
Our findings suggest that prevalence of cur­
rent asthma increases with increasing MUP 
concentrations, although the results were 
not as consistent for bedroom bed and living 
room upholstery as for the other sites. We 
found no clear indication of a threshold below 
which there was no increase in prevalence.
Wheezing was not significantly associ­
ated with elevated MUP levels in the total 
study population (Table 2). Most of those 
(71.4%) who reported either wheezing in 
the past month or in the past year did not 
report asthma symptoms. Because diseases 
other than asthma [e.g., chronic obstruc­
tive pulmonary disease (COPD)] might 
have contributed to wheezing, we conducted 
additional analysis in a subpopulation of indi­
viduals < 40 years of age (n = 1,541). In this 
subpopulation, wheezing is less likely to be 
associated with COPD because the bulk of the 
disease occurs in older age groups (Stang et al. 
2000). In the younger subpopulation, recent 
wheezing was more prevalent among subjects 
who had elevated MUP levels in their homes 
than among those who did not (25.1% vs. 
17.8%; p = 0.07 for difference). Table 3 of the 
Supplemental Material (http://www.ehponline.
org/  members/2008/11847/suppl.pdf) shows 
Figure 1. Adjusted ORs and 95% CIs for the association between current asthma and MUP concentration 
in the household (continuous variable, logistic regression). The house index (mean of site-specific con-
centrations) and site-specific ORs correspond to a 2-fold increase in MUP concentration adjusting for age, 
sex, race, education, smoking, and survey season. The ORs for atopic (A) and nonatopic (B) individuals are 
presented separately (in parentheses) because the observed association was modified by atopic status.
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Table 3. Current asthma in relation to MUP concen-
tration in the household, all subjects.
Logistic models  OR (95% CI)
(n = 2,028)  MUP ≤ 1.6 µg/g  MUP >  1.6 µg/g
Unadjusted model  1.00  1.41 (0.96–2.06)
Adjusted modela  1.00  1.40 (0.94–2.10)
aAdjusted for age, sex, race, education, smoking, and 
survey season.
Table 4. Current asthma in relation to MUP concentration in the household, stratified by atopic status.a
  OR (95% CI) 
Logistic models (n = 2,028)  Nonatopic  Atopic  p-Value for interaction
Unadjusted model  0.74 (0.35–1.59)  2.04 (1.22–3.43)  0.06
Adjusted modelb  0.69 (0.33–1.44)  1.93 (1.14–3.27)  0.05
Including other allergens     
  Fel d 1  0.69 (0.33–1.44)  1.92 (1.13–3.24)  0.05
  Can f 1  0.68 (0.32–1.43)  1.87 (1.10–3.21)  0.06
  Der f 1c  0.68 (0.32–1.42)  1.91 (1.13–3.28)  0.05
  Der p 1  0.67 (0.32–1.39)  1.95 (1.15–3.33)  0.04
  Bla g 1  0.72 (0.34–1.49)  2.02 (1.18–3.45)  0.05
 Alternaria alternatac  0.65 (0.31–1.35)  1.79 (1.04–3.07)  0.06
Including endotoxinc  0.65 (0.30–1.43)  1.79 (1.04–3.07)  0.07
Including dust weight  0.67 (0.32–1.41)  1.90 (1.12–3.23)  0.05
aAtopy assessed by reported doctor-diagnosed allergies; current asthma/no current asthma = 41/1,448 for nonatopic 
individuals, 126/413 for atopic individuals; reference group is MUP ≤ 1.6 µg/g. bAdjusted for age, sex, race, education, 
smoking, and survey season. cBecause of missing observations, these models include fewer observations than the other 
adjusted models.
Figure 2. Smoothed plots showing adjusted prevalence of current asthma by MUP concentration for the 
house index and each sampling location. The estimated prevalence is adjusted for age, sex, race, education, 
smoking, and survey season.
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ORs for recent wheezing (in the past month 
and/or in the past year) among the younger age 
groups. Our results suggest that the association 
is modified by atopic status. After adjusting 
for potential confounders, elevated MUP lev­
els in any location in the home significantly 
increased the odds of recent wheezing among 
atopic individuals (adjusted OR = 2.83; 95% 
CI, 1.35–5.96), but we found no association 
in nonatopic individuals (adjusted OR = 1.34; 
95% CI, 0.75–2.39).
Discussion
The NSLAH was the first study to examine 
the role of residential mouse allergen expo­
sures in relation to asthma in nationally rep­
resentative sample of U.S. households. We 
found that elevated levels of mouse allergen 
significantly increased the likelihood of hav­
ing asthma­related symptoms among atopic 
individuals. In contrast, we found no associa­
tion in nonatopic individuals. The association 
remained consistent after adjusting for poten­
tial confounders. Therefore, our findings sug­
gest that mouse allergen exposure in the home 
is an important risk factor for allergic asthma 
and contributes independently to asthma 
morbidity among allergic individuals.
In allergic asthma, allergens play a key role 
in triggering and exacerbating asthma symp­
toms (Langley et al. 2003; Nelson 2000). 
Because people spend most of their time 
indoors, especially at home, allergen exposures 
in the home environment are of great impor­
tance in relation to asthma (Leech et al. 2002). 
Although mouse allergen is a well­recognized 
and widely studied allergen in occupational 
settings (Bush and Stave 2003; Phipatanakul 
2002), it has only recently identified as a 
household allergen that may influence asthma 
morbidity in domestic settings. To date, most 
research has focused on inner­city homes in 
which mouse allergen has been found to be 
ubiquitous (Chew et al. 2003, 2006; Matsui 
et al. 2005, 2006, 2007; Phipatanakul et al. 
2000a, 2000b). The results from the NSLAH, 
however, suggest that the presence of mouse 
allergen in U.S. homes is surprisingly com­
mon even outside inner­city environments. 
Although exposure levels tend to be higher in 
low­income, urban neighborhoods (Matsui 
et al. 2004; Simons et al. 2007), our find­
ings demonstrate that elevated levels are not 
restricted to those environments. However, 
restricting the analysis to low­income, urban 
homes in the NSLAH, the prevalence and 
distributions of mouse allergen compared well 
with previous findings from inner­city pop­
ulations. For example, in the NCICAS and 
NSLAH, 95% of low­income urban homes 
had detectable mouse allergen levels in at least 
one room. Detectable levels of mouse allergen 
in kitchens were also comparable (83% in the 
NSLAH; 87% in the NCICAS). However, 
the prevalence of elevated mouse allergen 
  levels (> 1.6 µg/g) in kitchens was higher in 
the NCICAS than in the NSLAH (50% in 
the NCICAS; 33% in the NSLAH) (Cohn 
et al. 2004; Phipatanakul et al. 2000a). On the 
other hand, some studies in low­income urban 
populations have observed lower mouse aller­
gen levels than those found in the NCICAS 
(Chew et al. 2006).
In the NSLAH, elevated mouse allergen 
levels were associated with asthma­related out­
comes. After adjusting for potential confound­
ers, including the presence of other indoor 
allergens, endotoxin, or dust weight, elevated 
levels of mouse allergen (> 1.6 µg/g) in the 
home increased the odds of having asthma 
symptoms in the past year approximately 
2­fold. However, the observed association was 
modified by atopic status; we found the asso­
ciation in atopic but not in nonatopic indi­
viduals. Because elevated mouse allergen levels 
have been associated with several other envi­
ronmental exposures, particularly exposures 
that relate to poor housing conditions (Simons 
et al. 2007), we cannot exclude the possibility 
that additional factors may have contributed 
to current asthma symptoms. Indeed, we have 
previously shown that Alternaria and endotoxin 
exposures contribute to asthma morbidity in 
this population (Salo et al. 2006; Thorne et al. 
2005). However, our results suggest an inde­
pendent association between asthma symptoms 
and mouse allergen levels because the observed 
association did not change appreciably after 
adjusting for potential confounders.
Although degree of atopy has been associ­
ated with mouse sensitivity and elevated mouse 
allergen levels among asthmatic inner­city chil­
dren (Phipatanakul et al. 2000b), atopy per se 
was not associated with mouse allergen levels 
in the NSLAH. This may reflect differences 
in population characteristics: The NCICAS 
included only asthmatic children, whereas the 
NSLAH sample represented the general popu­
lation. Studies have shown that the prevalence 
and degree of atopy tend to be higher among 
asthmatic inner­city children than among the 
general U.S. population (Arbes et al. 2005; 
Crain et al. 2002; Eggleston et al. 1998; 
Stevenson et al. 2001). Because we were not 
able to ascertain the specificity or degree of 
atopy in the NSLAH, atopy reflects subjects’ 
allergic status in general, not specific sensiti­
zation to mouse allergen. Although atopy is 
often confirmed by clinical measures (serum 
IgE, skin prick tests), the diagnosis of clini­
cally relevant allergy also depends on symp­
tom history. The presence of allergen­specific 
antibodies or a positive skin test response to a 
specific allergen does not necessarily mean that 
a patient has clinically significant symptoms 
when exposed to an allergen (Pastorello et al. 
1995). However, questionnaire­based data may 
underestimate the prevalence of atopy because 
questionnaires are unlikely sensitive enough to 
detect all individuals who are atopic (Lakwijk 
et al. 1998). We acknowledge that the lack of 
objective information on study subjects’ atopic 
status is a limitation, but findings from the 
NCICAS suggest that mouse allergen concen­
trations > 1.6 µg/g are associated with increased 
risk for IgE­mediated mouse sensitization.
Because the literature­derived cutoff point 
that we used to dichotomize the exposure vari­
able is somewhat arbitrary, we further charac­
terized the relationship between current asthma 
and mouse allergen levels by conducting addi­
tional statistical analyses, including modeling 
the exposure as continuous variable and using 
complementary modeling techniques. Our 
modeling results remained rather consistent 
regardless of the methods used. Most of the 
site­specific analyses supported the concept 
that the prevalence of current asthma increased 
with increasing mouse allergen concentrations, 
but the trend was less clear for bedroom bed 
and living room upholstery dusts. Although 
a recent study has suggested that the shape of 
the dose–response relationship between mouse 
allergen levels and allergen­specific sensitiza­
tion may not be linear, particularly at higher 
mouse allergen levels (Matsui et al. 2007), it is 
unlikely that the nonlinear shape of the smooth 
curves is associated with this phenomenon. In 
fact, mouse allergen levels in bedroom bed and 
living room upholstery dusts were lower than 
in the other sites. Furthermore, these two sites 
had more missing observations than did floor 
dust samples, which may have influenced the 
modeling accuracy.
Wheezing was not significantly associ­
ated with elevated mouse allergen levels in the 
total study population. Although wheezing 
is a common symptom of asthma, a variety 
of respiratory disorders that lead to airway 
narrowing or obstruction can be associated 
with wheezing (Gong 1990). Because most 
of those who reported recent wheezing did 
not report asthma symptoms, we hypothe­
sized that diseases other than asthma (e.g., 
COPD) might have contributed to wheezing. 
However, COPD is a slowly progressive dis­
ease and rarely occurs in individuals < 40 years 
of age (Halbert et al. 2003; Stang et al. 2000). 
When we restricted our analysis to a younger 
subpopulation (< 40 years of age), wheezing 
was strongly associated with elevated mouse 
allergen levels among atopic individuals. 
Consistent with reported asthma symptoms, 
we saw the strongest effects with elevated 
MUP levels in bedroom floor and living room 
dusts. We recognize that the wheezing­related 
results should be interpreted with some cau­
tion because we were not able to ascertain and 
differentiate whether wheezing resulted from 
asthma, COPD, or other respiratory disorders.
We acknowledge that our study has limita­
tions. Because of the cross­sectional nature of Residential exposure to mouse allergen and asthma
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r 3 | March 2009  391
the study, temporal relationships may be diffi­
cult to determine. Therefore, we focused mainly 
on asthma­related outcomes in the recent past. 
We lacked detailed sensitization data (e.g., skin 
prick test, specific IgE) but assessed atopy on 
self­reported physician­diagnosed allergies. 
Although airborne allergen concentrations 
are considered more relevant measures of per­
sonal exposure, large­scale epidemiologic stud­
ies traditionally use measurement of allergen 
concentration in reservoir dust as a surrogate 
measure of exposure, largely because of prac­
tical and financial reasons. In this study, we 
assessed mouse allergen levels in dust across 
multiple household sites, in order to character­
ize the exposure in detail. The NSLAH con­
ducted sampling in each geographic region 
throughout seasons to mitigate any possible 
seasonal bias. Although the cutoff point that 
we used to dichotomize the exposure for mod­
eling is somewhat arbitrary, findings from the 
NCICAS study have shown that mouse aller­
gen concentrations above this threshold have 
been associated with an increased risk for IgE­
mediated mouse sensitization (Phipatanakul 
et al. 2000b). Moreover, Matsui et al. (2005) 
have demonstrated that even with lower aller­
gen concentrations in dust, mouse allergen is 
detectable in the vast majority of air samples; 
in their study, 90% of the participants with 
> 0.5 µg/g of mouse allergen in settled dust 
samples had detectable levels of airborne mouse 
allergen in their home.
The major strength of the study is its 
national representativeness. Vojta et al. (2002) 
showed that the demographic characteristics 
of the weighted survey sample did not dif­
fer appreciably from characteristics of other 
national surveys, including the 1995 and 1997 
American Housing Survey and the 1998 and 
1999 Current Population Survey. Furthermore, 
asthma prevalence rates compared well with 
other national estimates (Centers for Disease 
Control and Prevention 2006). The NSLAH 
was the first study to evaluate the importance 
of residential mouse allergen exposures among 
the general U.S. population.
In summary, this study suggests that mouse 
allergen is an important household allergen in 
U.S. homes. We found that higher mouse aller­
gen levels significantly increased the likelihood 
of having atopic wheeze and/or asthma symp­
toms among allergic individuals. Our study 
extends prior research findings from inner­city 
populations to the general population. Further 
research, however, is required to develop and 
evaluate environmental control measures that 
cost­effectively reduce and sustain low mouse 
allergen levels in problem homes. To date, very 
little information on interventions targeting 
reductions in residential mouse allergen lev­
els is available (Phipatanakul et al. 2004). We 
encourage future studies to determine clinically 
relevant exposure levels for mouse allergen and 
to provide information on clinical benefits of 
effective interventions.
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